Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity

Alessandro Inno, Giulio Metro, Paolo Bironzo, Antonio M. Grimaldi, Elisabetta Grego, Vincenzo Di Nunno, Virginia Picasso, Francesco Massari, Stefania Gori

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Immune checkpoint inhibitors have emerged as an effective treatment for several tumor types and their use in clinical practice is expected to further increase in the immediate future. Although these agents are well tolerated, they are associated with a peculiar spectrum of toxicity, which is immune mediated and may potentially affect every organ. However, immune-related adverse events are mostly reversible if promptly diagnosed and adequately treated. Therefore, it is crucial that medical oncologists know how to diagnose and treat immune-related adverse events. This review focuses on the pathogenesis, clinical manifestations and management of immune-related toxicity of anti-CTLA-4 and anti-PD-1 antibodies.

Original languageEnglish
Pages (from-to)405-421
Number of pages17
JournalTumori
Volume103
Issue number5
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Antibodies
Neoplasms
Therapeutics
Oncologists

Keywords

  • Immune checkpoint inhibitors
  • Immune-related adverse events
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Inno, A., Metro, G., Bironzo, P., Grimaldi, A. M., Grego, E., Nunno, V. D., ... Gori, S. (2017). Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori, 103(5), 405-421. https://doi.org/10.5301/tj.5000625

Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. / Inno, Alessandro; Metro, Giulio; Bironzo, Paolo; Grimaldi, Antonio M.; Grego, Elisabetta; Nunno, Vincenzo Di; Picasso, Virginia; Massari, Francesco; Gori, Stefania.

In: Tumori, Vol. 103, No. 5, 01.09.2017, p. 405-421.

Research output: Contribution to journalReview article

Inno, A, Metro, G, Bironzo, P, Grimaldi, AM, Grego, E, Nunno, VD, Picasso, V, Massari, F & Gori, S 2017, 'Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity', Tumori, vol. 103, no. 5, pp. 405-421. https://doi.org/10.5301/tj.5000625
Inno, Alessandro ; Metro, Giulio ; Bironzo, Paolo ; Grimaldi, Antonio M. ; Grego, Elisabetta ; Nunno, Vincenzo Di ; Picasso, Virginia ; Massari, Francesco ; Gori, Stefania. / Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. In: Tumori. 2017 ; Vol. 103, No. 5. pp. 405-421.
@article{0df1ea82b1ae44dcae5c946ff7476340,
title = "Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity",
abstract = "Immune checkpoint inhibitors have emerged as an effective treatment for several tumor types and their use in clinical practice is expected to further increase in the immediate future. Although these agents are well tolerated, they are associated with a peculiar spectrum of toxicity, which is immune mediated and may potentially affect every organ. However, immune-related adverse events are mostly reversible if promptly diagnosed and adequately treated. Therefore, it is crucial that medical oncologists know how to diagnose and treat immune-related adverse events. This review focuses on the pathogenesis, clinical manifestations and management of immune-related toxicity of anti-CTLA-4 and anti-PD-1 antibodies.",
keywords = "Immune checkpoint inhibitors, Immune-related adverse events, Toxicity",
author = "Alessandro Inno and Giulio Metro and Paolo Bironzo and Grimaldi, {Antonio M.} and Elisabetta Grego and Nunno, {Vincenzo Di} and Virginia Picasso and Francesco Massari and Stefania Gori",
year = "2017",
month = "9",
day = "1",
doi = "10.5301/tj.5000625",
language = "English",
volume = "103",
pages = "405--421",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity

AU - Inno, Alessandro

AU - Metro, Giulio

AU - Bironzo, Paolo

AU - Grimaldi, Antonio M.

AU - Grego, Elisabetta

AU - Nunno, Vincenzo Di

AU - Picasso, Virginia

AU - Massari, Francesco

AU - Gori, Stefania

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Immune checkpoint inhibitors have emerged as an effective treatment for several tumor types and their use in clinical practice is expected to further increase in the immediate future. Although these agents are well tolerated, they are associated with a peculiar spectrum of toxicity, which is immune mediated and may potentially affect every organ. However, immune-related adverse events are mostly reversible if promptly diagnosed and adequately treated. Therefore, it is crucial that medical oncologists know how to diagnose and treat immune-related adverse events. This review focuses on the pathogenesis, clinical manifestations and management of immune-related toxicity of anti-CTLA-4 and anti-PD-1 antibodies.

AB - Immune checkpoint inhibitors have emerged as an effective treatment for several tumor types and their use in clinical practice is expected to further increase in the immediate future. Although these agents are well tolerated, they are associated with a peculiar spectrum of toxicity, which is immune mediated and may potentially affect every organ. However, immune-related adverse events are mostly reversible if promptly diagnosed and adequately treated. Therefore, it is crucial that medical oncologists know how to diagnose and treat immune-related adverse events. This review focuses on the pathogenesis, clinical manifestations and management of immune-related toxicity of anti-CTLA-4 and anti-PD-1 antibodies.

KW - Immune checkpoint inhibitors

KW - Immune-related adverse events

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85031101362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031101362&partnerID=8YFLogxK

U2 - 10.5301/tj.5000625

DO - 10.5301/tj.5000625

M3 - Review article

VL - 103

SP - 405

EP - 421

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 5

ER -